Sanofi reviews

Very few developmental opportunities or promotions are available. Company loyalty isn't a priority. Changing metric each quarter and innovation doesn't exists.

Senior management is inept - perhaps half the VPs are gone but there is more pruning to be done. Sanofi has purchased the company and is trying to sort this out but they seem bewildered by the vast array of problems. Genzyme manufacturing plants were under-managed and under-funded for years and this cannot be turned around overnight. People at all levels are working beneath their position as a way of compensating for a lack of proper management systems.